Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Navidea Biopharmaceuticals Inc (NYSE American:NAVB)

0.385
Delayed Data
As of Aug 22
 -0.0081 / -2.06%
Today’s Change
0.26
Today|||52-Week Range
1.16
-39.61%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$63.8M

Company Description

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. The company operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Contact Information

Navidea Biopharmaceuticals, Inc.
5600 Blazer Parkway
Dublin Ohio 43017-1367
P:(614) 793-7500
Investor Relations:

Employees

Shareholders

Mutual fund holders4.67%
Individual stakeholders14.52%
Other institutional13.89%

Top Executives

Mike M. GoldbergPresident, Chief Executive Officer & Director
Jed Andrew LatkinCFO, COO, Secretary & Treasurer
Frederick O. CopeChief Scientific Officer & Senior Vice President
William J. ReganChief Compliance Officer & SVP-Global Regulatory